# Ling Wong

> Ling Wong is a Series A investor at Sea Lane Ventures backing Biotechnology and Health Care. See 29 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sea Lane Ventures](https://shizune.co/investors/profile/sea-lane-ventures)
- Location: Seattle, United States
- Total investments: 29
- Last investment: Apr 2022
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lingwong1
- X (Twitter): http://twitter.com/LingWong
- Website: http://www.lingwong.com

Ling Wong is a Series A investor at Sea Lane Ventures in Seattle focused on Biotechnology and Health Care. Dr. Ling Wong is Founder and General Partner of Highbury Group and Sea Lane Ventures. She also serves as Senior Advisor to Lightspeed Venture Partners. Highbury Group was founded on the principle to be a true partner and champion to entrepreneurs, using science and technology to build companies that fundamentally transform the world for thebetterment of humanity today, and in the future.Dr. Wong draws from her unique background and experience as a scientist, entrepreneur, and investor to support and bring to market companies that exist at the intersection between health and technology. “I love to partner with mission-oriented founders working on transformational ideas that can have a positive, lasting impact on society – and do so by leveraging technology and science in a financially sustainable manner,” said Dr. Wong.Prior to Highbury, she served at the Gates Foundation where she helped to establish a $1.5B global investment portfolio and created a $200M early stage program to support early stage entrepreneurs in more than 60 countries.As a health and technology investor, Dr. Wong has been involved in some of the market’s most significant investments and exits. She has partnered with over fifteen $1B+ companies, including: Devoted Health, Orca Bio, Collective Health, Color, Apeel, Shape, Stripe, Offer Up, Rappi, Branch Metrics, Notion, Modern Animal, Wheel and Satellite Bio. Notable exits include: Anacor Pharmaceuticals (acquired by Pfizer for $5.2B), Genocea Biosciences (NASDAQ: GNCA), Visterra (acquired for $430M), Slack (NYSE: WORK), Guardant Health (NASDAQ: GH), and recently Singular Genomics (NASDAQ: OMIC).Dr. Wong holds a PhD from Harvard in Engineering Sciences, a BSc in Chemical Engineering and BSc in Biology from MIT. During her time at Harvard, she created the world’s first inhaled TB vaccine. Her scientific training has shaped how she assesses financial opportunities, both to create value and to benefit human health. Dr. Wong has always been passionate about seeking entrepreneurs and partners that are looking to disrupt the status quo in science and technology for the betterment of society.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8.1M–$82M |
| Series B | $32M–$300M |
| Series C | $90M–$450M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 21% |
| Health Care | 5 | 17% |
| Medical | 4 | 14% |
| Hospital | 2 | 7% |
| Software | 2 | 7% |

33 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 24% |
| Series B | 4 | 14% |
| Series C | 4 | 14% |
| Seed | 3 | 10% |
| Series D | 2 | 7% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 14 | 48% |
| Colombia | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Satellite Bio | Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. |  | Series A | Apr 21, 2022 |  |
| Satellite Bio | Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. | $82.5M |  | Mar 07, 2022 |  |
| Satellite Bio | Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. | $82.5M | Series A | Mar 07, 2022 |  |
| Curve Health | Curve Health is senior care without walls. It is a platform that's reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulancesor wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics, and smart billing into a single platform, resulting in higher quality care + significant return on investment while ensuring the most seamless patient experience. | $12M | Series A | Feb 06, 2022 |  |
| Wheel | Wheel is a healthcare technology company that brings together the tech infrastructure and clinicians to power Virtual Care and Telehealth. | $150M | Series C | Jan 19, 2022 |  |
| Devoted Health | Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technologyto enable a simplified experience, and by partnering with top providers for better health outcomes. | $1.2B | Series D | Oct 08, 2021 |  |
| Evermore | Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America. | $6M | Seed | Aug 19, 2021 |  |
| Shape Therapeutics | Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of thesetechnologies throughout the industry to develop effective treatments for as many patients as possible. | $112M | Series B | Jul 15, 2021 |  |
| Wheel | Wheel is a healthcare technology company that brings together the tech infrastructure and clinicians to power Virtual Care and Telehealth. | $50M | Series B | May 19, 2021 |  |
| BioAge Labs | BIOAGE discovers and develops drugs to treat aging and associated diseases. | $90M | Series C | Dec 03, 2020 |  |

10 of 29 investments shown.

## Co-investors
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 6 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 5 deals together
- [Correlation Ventures](https://shizune.co/investors/profile/correlation-ventures) — VC Fund, 4 deals together
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund, 4 deals together
- [Kapor Capital](https://shizune.co/investors/profile/kapor-capital) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together

## About Sea Lane Ventures

VC Fund · Chicago, United States

Sea Lane Ventures is an angel investor that invests in software service companies. It provides strategic investment as well as experience to its portfolio companies. Along with strategic investment, Sea Lane Ventures brings insight, experience and a key industry network to drive the success of its companies. Its investment choices are based on aconstant reflection of experience, market dynamics, and forward-thinking.It was founded in 2014 by Dr. Ling Wong in Chicago, Illinois.

1 contacts available at Sea Lane Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Ling Wong | General Partner | https://shizune.co/investors/profile/ling-wong |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Avalancha Ventures](https://shizune.co/investors/profile/avalancha-ventures) — VC Fund
- [Actions Capital (fka K50 Ventures)](https://shizune.co/investors/profile/k50ventures) — VC Fund
- [Magma Partners](https://shizune.co/investors/profile/magma-partners) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors](https://shizune.co/investors/biotech-angel-investors)
- [Biotech Angel Investors in United States](https://shizune.co/investors/biotech-angel-investors-united-states)
- [Biotechnology Angel Investors](https://shizune.co/investors/biotechnology-angel-investors)
- [Food and Beverage Investors in Colombia](https://shizune.co/investors/food-and-beverage-investors-colombia)
- [Food and Beverage Angel Investors in Colombia](https://shizune.co/investors/food-and-beverage-angel-investors-colombia)
- [Consumer Angel Investors in Colombia](https://shizune.co/investors/consumer-angel-investors-colombia)

## FAQ

### What does Ling Wong invest in?

Ling Wong invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 29 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Ling Wong's check size?

Ling Wong typically joins rounds of $8.1M–$82M at Series A, $32M–$300M at Series B and $90M–$450M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ling Wong participates in.

### When did Ling Wong last invest?

The most recent investment recorded for Ling Wong closed in Apr 2022. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co